Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY

Alnylam Pharmaceuticals — Technical Presentation (July 2026)

6 slides from Alnylam Pharmaceuticals's technical presentation, Jul 12, 2026

  1. Slide 1: Low plasminogen levels are not associated with an increased risk of arterial thrombosis

    Low plasminogen levels are not associated with an increased risk of arterial thrombosis Lynne Krohn1, Martina Lundberg Slingsby1, Ali Murad2, Luke Ward1, Aimee Deaton1, John Gansner1, Jeffrey Weitz3 1. Alnylam Pharmaceuticals, Cambridge, MA, United States 2. Alnylam Pharmaceuticals UK Ltd, Maidenhea

  2. Slide 2: Disclosure for presenter Jeffrey Weitz, MD

    Disclosure for presenter Jeffrey Weitz, MD Conflict Disclosure - if conflict of interest exists Research Support Alnylam Pharmaceuticals Director, Officer, Employee Shareholder Honoraria Alnylam Pharmaceuticals Advisory Committee Alnylam Pharmaceuticals Consultant Alnylam Pharmaceuticals ALN-6400: A

  3. Slide 3: ALN-6400: An Investigational RNAi Therapeutic

    ALN-6400: An Investigational RNAi Therapeutic Therapeutic Hypothesis • Plasminogen (PLG), which is mainly synthesized in the liver, is central to fibrinolysis • ALN-6400, an investigational RNA interference (RNAi) therapeutic that lowers the hepatic production of PLG, is being studied for the treatm

  4. Slide 4: Methodology for Computational Analyses in the UK Biobank

    Methodology for Computational Analyses in the UK Biobank Using human genetic and proteomic data from the UK Biobank, we assessed whether low plasma PLG levels were associated with an increased risk of myocardial infarction, ischaemic stroke, and arterial thrombosis • Linear regression was used to te

  5. Slide 5: Low PLG Levels Are Not Associated With Arterial Thrombosis

    Low PLG Levels Are Not Associated With Arterial Thrombosis PLG level has no correlative or causal relationship with risk for arterial thrombosis Increased risk found in positive control • In contrast to low levels of PLG, individuals with low levels of Protein S are at higher risk for all measured p

  6. Slide 6: Conclusion

    Conclusion • In this analysis of UK Biobank data, low PLG levels were not associated with an increased risk of myocardial infarction, ischaemic stroke, or arterial thrombosis • Together with prior work, these findings suggest that lowering plasma PLG with an RNAi therapeutic is unlikely to increase

Alnylam Pharmaceuticals — Technical Presentation (July 2026) on 6ix